Pharmacology/Pharmaceutical Industry
WHO challenges Pfizer and Moderna to openly share their know-how to accelerate COVID vaccine production.
5 Jul, 2021 | 02:36h | UTC
Joint COVAX Statement on the Equal Recognition of Vaccines – COVAX urges all government authorities to recognize as fully vaccinated all people who have received COVID-19 vaccines that have been deemed safe and effective by WHO.
5 Jul, 2021 | 02:39h | UTCJoint COVAX Statement on the Equal Recognition of Vaccines – World Health Organization
Commentary on Twitter (thread – click for more)
#COVAX urges all government authorities to recognize as fully vaccinated all who have received #COVID19 vaccines approved by WHO or one of 11 approved Stringent Regulatory Authorities, when making decisions on who is able to travel or attend events.
?https://t.co/udYVrYTdMg pic.twitter.com/DihCPUmS8F
— World Health Organization (WHO) (@WHO) July 1, 2021
Opinion | Covid is a greater risk to young people than the vaccines.
5 Jul, 2021 | 02:34h | UTCCovid Is a Greater Risk to Young People Than the Vaccines – The New York Times
Counterpoint: Weighing myocarditis cases, ACIP failed to balance the harms vs benefits of 2nd doses – by Wesley Pegden AND Vaccine-Induced Myocarditis Concerns Demand Respect, Not Absolutism – Medscape (free registration required)
Commentary on Twitter
“Realize the choice is not ‘vaccinate or do nothing.’ It’s ‘vaccinate or eventually contract the coronavirus,’ and the risks that come with it.”
My latest with @celinegounder and @EMDocinTraining@NYTOpinion @acsifferlin https://t.co/wGugCuWgSs
— Jeremy Faust MD MS (ER physician) (@jeremyfaust) July 4, 2021
Russia pushes ahead with open license approach to Sputnik V – despite WHO concerns over manufacturing practices.
5 Jul, 2021 | 02:35h | UTC
Roundup on Covid vaccines | A Big Hit, A Big Miss, & Mixed Vaccine Schedules: The 18-Month Mark.
5 Jul, 2021 | 02:31h | UTCA Big Hit, A Big Miss, & Mixed Vaccine Schedules: The 18-Month Mark – Absolutely Maybe Blog
Commentary on Twitter
My latest roundup on Covid vax: a big hit, a big miss, & mixed vaccine schedules. 15 vaxes with phase 3 results coming up to the 18-month mark! More than 20 controlled community impact studies now, & lots on immunocompromise | New @PLOS https://t.co/HEsuFc4af3 #IC
— Hilda Bastian, PhD (@hildabast) July 2, 2021
Why Covid-19 outbreaks in countries using Chinese vaccines don’t necessarily mean the shots have failed.
5 Jul, 2021 | 02:30h | UTC
What are the Sinopharm and Sinovac vaccines? And how effective are they? Two experts explain.
5 Jul, 2021 | 02:28h | UTC
Proof-of-concept trial: A Transglutaminase 2 inhibitor attenuated gluten-induced duodenal mucosal damage in patients with celiac disease.
5 Jul, 2021 | 01:56h | UTCCommentary: NEJM: First Effective Non-Dietary Treatment Of Celiac Disease – MedicalResearch
Germany issues world’s strongest recommendation for mixing Covid-19 vaccines.
5 Jul, 2021 | 02:27h | UTCGermany issues world’s strongest recommendation for mixing Covid-19 vaccines – CNN
Aspirin and cancer survival: a systematic review and meta-analyses of 118 observational studies of aspirin and 18 cancers.
5 Jul, 2021 | 01:42h | UTCCommentaries: Expert reaction to review and analysis of observational studies on aspirin and cancer survival – Science Media Centre AND Major review of studies: Aspirin could cut risk of death in cancer patients by 20% – Cardiff University
“It is randomized trials that provide definitive evidence to consider changes to clinical practice. The results of this review provide impetus for cancer patients to consider participation in these trials” (from Science Media Centre)
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations.
5 Jul, 2021 | 01:30h | UTCAntipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations – Drugs
[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.
2 Jul, 2021 | 11:47h | UTCMixing Covid jabs has good immune response, study finds – BBC
Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations.
2 Jul, 2021 | 11:39h | UTCCommentary: Blood clots related to AstraZeneca/Oxford vaccine can be mitigated with early detection – MedicalXpress
Viewpoint | Sharing technology and vaccine doses to address global vaccine inequity and end the COVID-19 pandemic.
2 Jul, 2021 | 11:22h | UTC
[Press release] J&J single-shot COVID-19 vaccine generates strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.
2 Jul, 2021 | 11:38h | UTCCommentary: J&J Covid Shot Neutralizes Delta Variant, Company Says – Bloomberg (a few articles per month are free)
The Management of Restless Legs Syndrome: An Updated Algorithm
2 Jul, 2021 | 11:12h | UTCThe Management of Restless Legs Syndrome: An Updated Algorithm – Mayo Clinic Proceedings
COVID-19 vaccines reduce severity, length, viral load for those who still get infected.
1 Jul, 2021 | 09:57h | UTCOriginal study: Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines – New England Journal of Medicine
Commentary on Twitter
The @CDCgov trial to rigorously assess mRNA vaccination suppression of covid infections as assessed with frequent NP swabs in nearly 4,000 participants
91% efficacy of blocking transmission of infection (2 doses); 40% reduction of viral load https://t.co/tI6LECbw42 pic.twitter.com/y85Vd9ih5A— Eric Topol (@EricTopol) June 30, 2021
RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.
1 Jul, 2021 | 09:59h | UTCSafety and Efficacy of NVX-CoV2373 Covid-19 Vaccine – New England Journal of Medicine
Audio interview: Audio Interview: Another New Covid-19 Vaccine – New England Journal of Medicine
Related: Opinion | The mRNA vaccines are extraordinary, but Novavax is even better
RCT: Similar outcomes with 5 vs. 2 years of zoledronate treatment following adjuvant chemotherapy in early breast cancer.
1 Jul, 2021 | 09:50h | UTCOriginal Study: Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Case Series: Myocarditis following immunization with mRNA COVID-19 vaccines.
30 Jun, 2021 | 10:22h | UTCSee also: Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination – JAMA Cardiology
Editorials: Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines AND Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working
Commentary: More Evidence Links Myocarditis to mRNA COVID-19 Vaccines – TCTMD
Commentary on Twitter
2 new reports of myocarditis after mRNA vaccination documenting its rare occurrence
23 males serving in the military among 2.8 million doses givenhttps://t.co/yPbYxkuSHi
4 cases in North Carolina, including a 70-year-old womanhttps://t.co/Iwj2Hx6O2U@JAMACardio pic.twitter.com/fv2JoOFAyt— Eric Topol (@EricTopol) June 29, 2021
Systematic Review: Cilostazol for intermittent claudication – “Cilostazol has been shown to improve walking distance in people with intermittent claudication. However, participants taking cilostazol had higher odds of experiencing headache”.
1 Jul, 2021 | 09:42h | UTCCilostazol for intermittent claudication – Cochrane Library
Summary: Cilostazol for peripheral arterial disease – Cochrane Library
Exclusive-WHO estimates COVID-19 boosters needed yearly for most vulnerable.
30 Jun, 2021 | 10:17h | UTCExclusive-WHO estimates COVID-19 boosters needed yearly for most vulnerable – Reuters
Related: CDC group says there isn’t enough data yet to recommend Covid booster shots – CNBC
Should I get my second AstraZeneca dose? Yes, it almost doubles your protection against Delta.
30 Jun, 2021 | 10:11h | UTCRelated: Effectiveness of COVID-19 vaccines against the B.1.617.2 variant – medRxiv
M-A: SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure.
30 Jun, 2021 | 10:08h | UTC
Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.
29 Jun, 2021 | 10:09h | UTCInvited commentary: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases
Commentary on Twitter
NEW—A phase 1/2 clinical trial of #CoronaVac in 550 children and adolescents aged 3-17 years in China suggests two doses of the vaccine are safe and generate a strong antibody response. Read in @TheLancetInfDis: https://t.co/eXSagRu1Cs pic.twitter.com/fOKNLUjNwc
— The Lancet (@TheLancet) June 28, 2021